---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-056122"
form_type: "8-K"
ticker: "PRME"
cik: "0001894562"
company_name: "Prime Medicine, Inc."
filed_at: "2025-03-18T23:59:59+00:00"
generated_at: "2026-05-24T14:38:29.615514+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Prime Medicine unveils preclinical AATD program with up to 72% gene correction, IND/CTA expected mid-2026

## Summary
- AATD program targets E342K (Pi*Z) mutation in SERPINA1 gene using LNP-delivered Prime Editors.
- In humanized mice, up to 72% precise correction of SERPINA1 in hepatocytes, restoring >95% serum AAT to corrected isoform.
- Serum M-AAT levels well above 20µM, indicating restoration to normal levels in mouse model.
- Company expects to file IND and/or CTA for AATD program in mid-2026.

## SEC filing metadata
- accession: 0001193125-25-056122
- form_type: 8-K
- ticker: PRME
- cik: 0001894562
- company_name: Prime Medicine, Inc.
- filed_at: 2025-03-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1894562/000119312525056122/0001193125-25-056122-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1894562/000119312525056122/d908678d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-056122
- JSON: https://secwatch.observer/filing/0001193125-25-056122.json
- Plain text: https://secwatch.observer/filing/0001193125-25-056122.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.